CDI-988 for Norovirus
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called CDI-988 to determine if it can reduce symptoms when exposed to norovirus, which causes stomach issues like vomiting and diarrhea. Participants will receive either CDI-988 or a placebo and then be exposed to the virus to compare symptom severity between groups. The study will measure virus levels in stool samples and examine how the body processes the treatment. The trial seeks healthy individuals aged 18 to 49 who know their fucosyl transferase 2 (FUT2) secretor status, which influences the body's response to certain infections. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or high-dose steroids, you may not be eligible to participate.
Is there any evidence suggesting that CDI-988 is likely to be safe for humans?
Research has shown that CDI-988 is generally safe for people. In a previous study, researchers administered CDI-988 to healthy adults, and the results indicated it was safe to use. Most participants did not experience serious side effects, and no major health issues were reported. This is encouraging for those considering joining the trial, as it suggests the treatment has been safe in past human tests.12345
Why do researchers think this study treatment might be promising?
CDI-988 is unique because it targets norovirus, which currently lacks a specific antiviral treatment. Most existing options, like oral rehydration solutions and antiemetic drugs, only manage symptoms rather than tackling the virus itself. Researchers are excited about CDI-988 because it introduces a novel approach to treating norovirus by potentially inhibiting the virus directly. This could mean faster relief from symptoms and reduced transmission, making it a groundbreaking advancement in managing this common and highly contagious infection.
What evidence suggests that CDI-988 might be an effective treatment for norovirus?
Research has shown that CDI-988, which participants in this trial may receive, effectively targets important norovirus types, specifically GII.4 and GII.17. In studies, CDI-988 targets key proteins that the virus needs to grow and spread. Early results from human trials suggest that CDI-988 can lessen norovirus symptoms, which often include uncomfortable issues like vomiting and diarrhea. While more information is needed, the drug's ability to block these vital proteins makes it a promising option for treating norovirus infections.12345
Who Is on the Research Team?
Nadine Rouphael, MD
Principal Investigator
Hope Clinic of the Emory Vaccine Center
Are You a Good Fit for This Trial?
This trial is for healthy adults who can safely be exposed to the Snowy Mountain Virus, which causes symptoms similar to Norovirus. Participants must not have any known immunity or previous exposure to this virus and should be in good health without chronic medication use that could affect the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either CDI-988 or placebo orally before receiving a norovirus challenge virus and continue for 5 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including measuring the amount of virus in stool samples and side effects
What Are the Treatments Tested in This Trial?
Interventions
- CDI-988
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cocrystal Pharma, Inc.
Lead Sponsor